nanotech-biotech-biomed-pharmaceutica.blogspot.com
Nanotech,Biotech, Biomed and Pharmaceutical News: Medtronic Announces Exclusive Licensing of Arbor Surgical Technologies Pericardial Heart Valve
http://nanotech-biotech-biomed-pharmaceutica.blogspot.com/2008/01/medtronic-announces-exclusive-licensing.html
Nanotech,Biotech, Biomed and Pharmaceutical News. A blog about Nanotech,Biotech, Biomed and Pharmaceutical News. Enter your search terms. Monday, January 28, 2008. Medtronic Announces Exclusive Licensing of Arbor Surgical Technologies Pericardial Heart Valve. According to the Millennium Research Group, more than 106,000 heart valves are expected to be implanted in the in the U.S. in 2008. Medtronic, Inc., ( www.medtronic.com. Arbor Surgical Technologies, Inc., ( www.arborsurgical.com. Technology News, Ea...
nanotech-biotech-biomed-pharmaceutica.blogspot.com
Nanotech,Biotech, Biomed and Pharmaceutical News: GlaxoSmithKline and Theravance announce start of large Phase 2B ICS and LABA studies for asthma in the Horizon programme
http://nanotech-biotech-biomed-pharmaceutica.blogspot.com/2008/01/glaxosmithkline-and-theravance-announce.html
Nanotech,Biotech, Biomed and Pharmaceutical News. A blog about Nanotech,Biotech, Biomed and Pharmaceutical News. Enter your search terms. Thursday, January 3, 2008. GlaxoSmithKline and Theravance announce start of large Phase 2B ICS and LABA studies for asthma in the Horizon programme. In a recently-completed Phase 2 study, ‘698 demonstrated once-a-day efficacy in patients with moderate asthma, with significant improvements in lung function in excess of 200mL seen within the first two weeks of dosi...
nanotech-biotech-biomed-pharmaceutica.blogspot.com
Nanotech,Biotech, Biomed and Pharmaceutical News: Unique Lens Material Helps Minimize Contact Lens Wearers' Discomfort And Dryness Symptoms Under Adverse Environmental Conditions, Study Shows
http://nanotech-biotech-biomed-pharmaceutica.blogspot.com/2008/01/unique-lens-material-helps-minimize.html
Nanotech,Biotech, Biomed and Pharmaceutical News. A blog about Nanotech,Biotech, Biomed and Pharmaceutical News. Enter your search terms. Monday, January 28, 2008. Unique Lens Material Helps Minimize Contact Lens Wearers' Discomfort And Dryness Symptoms Under Adverse Environmental Conditions, Study Shows. Senofilcon A has previously shown promising results for reducing lens-wear related symptoms of dryness and discomfort," she adds. "This study shows that contact lenses made with senofilcon A may be ...
nanotech-biotech-biomed-pharmaceutica.blogspot.com
Nanotech,Biotech, Biomed and Pharmaceutical News: Confirma And GE Healthcare Expand Strategic Partnership
http://nanotech-biotech-biomed-pharmaceutica.blogspot.com/2007/12/confirma-and-ge-healthcare-expand.html
Nanotech,Biotech, Biomed and Pharmaceutical News. A blog about Nanotech,Biotech, Biomed and Pharmaceutical News. Enter your search terms. Tuesday, December 18, 2007. Confirma And GE Healthcare Expand Strategic Partnership. 8220;This amendment demonstrates our commitment to GE Healthcare and its customers,” said Wayne Wager, President and CEO, Confirma. “We will offer customers expertise and support that continue to improve confidence in breast MRI.”. About Confirma Customer Support. Confirma supports a v...
nanotech-biotech-biomed-pharmaceutica.blogspot.com
Nanotech,Biotech, Biomed and Pharmaceutical News: Invitrogen Enters Non-Coding RNA Licensing Agreement with IMBcom
http://nanotech-biotech-biomed-pharmaceutica.blogspot.com/2008/01/invitrogen-enters-non-coding-rna.html
Nanotech,Biotech, Biomed and Pharmaceutical News. A blog about Nanotech,Biotech, Biomed and Pharmaceutical News. Enter your search terms. Thursday, January 17, 2008. Invitrogen Enters Non-Coding RNA Licensing Agreement with IMBcom. Researchers at the University of Queensland developed an algorithm that has predicted tens of thousands of unique human and mouse probe sequences relating to coding and non-coding RNA. John Mattick, professor of Molecular Biology at the University of Queensland added, "It appe...
nanotech-biotech-biomed-pharmaceutica.blogspot.com
Nanotech,Biotech, Biomed and Pharmaceutical News: GlaxoSmithKline and Theravance announce expansion of the Horizon programme with start of large Phase 2B study of LABA in COPD patients
http://nanotech-biotech-biomed-pharmaceutica.blogspot.com/2008/02/glaxosmithkline-and-theravance-announce.html
Nanotech,Biotech, Biomed and Pharmaceutical News. A blog about Nanotech,Biotech, Biomed and Pharmaceutical News. Enter your search terms. Tuesday, February 26, 2008. GlaxoSmithKline and Theravance announce expansion of the Horizon programme with start of large Phase 2B study of LABA in COPD patients. Darrell Baker, SVP GSK Respiratory Medicines Development Centre said, “Delivering a once-daily treatment for asthma and COPD, where there remains a considerable unmet need, is a priority. We believ...8220;We...
nanotech-biotech-biomed-pharmaceutica.blogspot.com
Nanotech,Biotech, Biomed and Pharmaceutical News: Submission of Marketing Authorisation Application for VELCADE (bortezomib) in Europe
http://nanotech-biotech-biomed-pharmaceutica.blogspot.com/2008/01/submission-of-marketing-authorisation.html
Nanotech,Biotech, Biomed and Pharmaceutical News. A blog about Nanotech,Biotech, Biomed and Pharmaceutical News. Enter your search terms. Tuesday, January 8, 2008. Submission of Marketing Authorisation Application for VELCADE (bortezomib) in Europe. Janssen-Cilag International NV, has submitted a Marketing Authorization Application to the European Medicines Evaluations Agency for the use of VELCADE (Bortezomib) for the treatment of patients with previously untreated multiple myeloma (MM). Multiple myelom...
nanotech-biotech-biomed-pharmaceutica.blogspot.com
Nanotech,Biotech, Biomed and Pharmaceutical News: GlaxoSmithKline and Synta announce elesclomol granted US orphan drug designation by the FDA
http://nanotech-biotech-biomed-pharmaceutica.blogspot.com/2008/01/glaxosmithkline-and-synta-announce.html
Nanotech,Biotech, Biomed and Pharmaceutical News. A blog about Nanotech,Biotech, Biomed and Pharmaceutical News. Enter your search terms. Monday, January 28, 2008. GlaxoSmithKline and Synta announce elesclomol granted US orphan drug designation by the FDA. 8220;We are pleased that the FDA granted elesclomol orphan drug status for the treatment of metastatic melanoma,” said Eric Jacobson, M.D., Senior Vice President and Chief Medical Officer, Synta Pharmaceuticals. “With the incide...8220;Orphan drug stat...
nanotech-biotech-biomed-pharmaceutica.blogspot.com
Nanotech,Biotech, Biomed and Pharmaceutical News: Medtronic and Weigao Announce Joint Venture in China
http://nanotech-biotech-biomed-pharmaceutica.blogspot.com/2007/12/medtronic-and-weigao-announce-joint.html
Nanotech,Biotech, Biomed and Pharmaceutical News. A blog about Nanotech,Biotech, Biomed and Pharmaceutical News. Enter your search terms. Tuesday, December 18, 2007. Medtronic and Weigao Announce Joint Venture in China. Closing of the transaction is subject to various conditions, including approval of the Chinese regulators and Weigao’s shareholders. 8220;China is key to our global strategy as we continue to expand our geographic footprint,” said Bill Hawkins, Medtronic president and CEO. ̶...Headqua...
nanotech-biotech-biomed-pharmaceutica.blogspot.com
Nanotech,Biotech, Biomed and Pharmaceutical News: Medtronic Launches AneuRx AAAdvantage Stent Graft on New Xcelerant® Hydro Delivery System in U.S for Minimally Invasive Treatment of Abdominal Aortic
http://nanotech-biotech-biomed-pharmaceutica.blogspot.com/2008/01/medtronic-launches-aneurx-aaadvantage.html
Nanotech,Biotech, Biomed and Pharmaceutical News. A blog about Nanotech,Biotech, Biomed and Pharmaceutical News. Enter your search terms. Thursday, January 10, 2008. Medtronic Launches AneuRx AAAdvantage Stent Graft on New Xcelerant Hydro Delivery System in U.S for Minimally Invasive Treatment of Abdominal Aortic. Medtronic, Inc. ( www.medtronic.com. Headquartered in Minneapolis, is the global leader in medical technology – alleviating pain, restoring health, and extending life for millions of peop...